Molecular Instruments® has announced a strategic partnership with Visiopharm, aiming to combine AI-Driven Precision Pathology with HCR™ Pro Assays to advance clinical-grade RNA-ISH. This collaboration brings MI's clinical-grade HCR™ platform with Visiopharm's Oncotopix® Discovery software, empowering users with a highly flexible, deep learning approach to precise and efficient image analysis for RNA-ISH assays.